Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
L., Hsu, Y
Civil No
Contact: Errol Zhou (Mr.) Tel: +86-551-65523315 Mobile/WhatsApp: +86 17705606359 QQ: 196299583 Skype: [email protected] Email: [email protected] Add: 1002, Huanmao Building, No.105, Mengcheng Road, Hefei City, 230061, China Eli Lilly recently announced that detailed results of the Phase 3 SURPASS-4 (NCT03730662) clinical trial evaluating the dual-acting GIP and GLP-1 receptor agonist tirzepatide (LY3298176) for the treatment of type 2 diabetes have been published in top international medical journals "The Lancet" (The Lancet)
Buenos das Marga
US$ 25.28
US$ 29.26
US$ 29.13
US$ 24.80
